Related Experiment Video
Updated: Jan 8, 2026
Author Spotlight: Development and Evaluation of a Compound Acne Rodent Model Using C. acnes and Oleic Acid
Published on: November 1, 2024
Incidence of Acne in Women Using the Levonorgestrel-Releasing Intrauterine Device: A Systematic Review and
Elaine Cristina Fontes de Oliveira1, Frederico Timm Rodrigues de Sousa1, Felipe Augusto Oliveira Lemos1
1Federal University of Minas Gerais, Belo Horizonte, Brazil.
Background:
The levonorgestrel-releasing intrauterine system (LNG-IUS) is a widely used long-term contraceptive with high continuation rates, but acne may lead to discontinuation.
Objectives:
To evaluate the incidence of acne among LNG-IUS users.
Search Strategy:
A systematic search was conducted in PubMed, Embase, and Cochrane Central from inception to September 2024.
Selection Criteria:
Randomised clinical trials (RCTs) analysing patients of any age using LNG-IUS at 52 mg, 19.5 mg, or 13.5 mg, with acne reported as an outcome, were included.
Data Collection And Analysis:
Statistical analyses were conducted using OpenMeta. Chi-square and Z-tests assessed differences between groups, and study quality was appraised using the ROB-2 tool.
Main Results:
Of 587 studies identified, nine RCTs met inclusion criteria, comprising 6305 LNG-IUS users. The overall acne incidence was 15.0% (95% CI 9.8%-20.3%). Among 2295 users of LNG-IUS 52 mg, incidence reached 19.5% (95% CI 5.2%-33.7%), whereas in 2322 users of LNG-IUS 13.5 mg it was 13.1% (95% CI 8.3%-17.9%) (p < 0.001). Two trials evaluated the 19.5 mg device but data were insufficient for pooling. Studies enrolling younger women (mean age ~24 years) reported an incidence of 19.3% (95% CI 11.0%-27.5%). Excluding Suhonen et al. yielded pooled proportions of 11.9% (95% CI 1.1%-22.7%) for LNG-IUS 52 mg users, 10.8% (95% CI 6.1%-15.5%) when all dosages were combined, and 9.9% (95% CI 9.0%-10.9%) among young women. Heterogeneity remained substantial in the overall and dosage-specific analyses (I2≈95%-97%); it was eliminated in the young women subgroup (I2 = 0%).
Conclusions:
LNG-IUS 52 mg users showed a higher incidence of acne compared with those using LNG-IUS 13.5 mg. Studies enrolling younger women also showed a higher incidence. These findings suggest that device dosage and age influence acne occurrence among LNG-IUS users.
Trial Registration:
PROSPERO registration number: CRD42024588771.
More Related Videos
Related Concept Videos
01:22Birth Control Methods
01:26Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
01:22Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:24Disorders of the Female Reproductive System
01:08Prevalence and Incidence
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...